In Vitro Susceptibility of Gentamicin-Resistant
            <i>Enterobacteriaceae</i>
            and
            <i>Pseudomonas aeruginosa</i>
            to Netilmicin and Selected Aminoglycoside Antibiotics

Meyer, Richard D.; Kraus, Linda L.; Pasiecznik, Karen A.

doi:10.1128/aac.10.4.677

Cited by 29 publications

(31 citation statements)

References 17 publications

Supporting

Mentioning

Contrasting

Unclassified

Order By: Relevance

“…Not noted in Table 3 (5,7,14). However, organisms resistant to gentamicin have been frequently less susceptible to netilmicin than to amikacin (7,13), as demonstrated in this study. This generally superior activity of amikacin against aminoglycoside-resistant bacteria may be attributable to the isolation of only one enzyme capable of inactivating this drug (17).…”

mentioning

confidence: 49%

Outbreak of Multiply Drug-Resistant Proteus mirabilis Originating in a Surgical Intensive Care Unit: In Vitro Susceptibility Pattern

Yoshikawa

Shibata

Chow

et al. 1978

Antimicrob Agents Chemother

View full text Add to dashboard Cite

A multiply drug-resistant strain of Proteus mirabilis was isolated from 14 patients on a surgical service. Antimicrobial susceptibility studies demonstrated that the organism was highly resistant to numerous antibiotics, including gentamicin, tobramycin, and sisomicin. The organism was susceptible in vitro to amikacin but had low-level resistance to netilmicin. In vitro susceptibility studies with combinations of cephalothin with netilmicin and trimethoprim with sulfamethoxazole showed these drugs to be synergistic. Other drug combinations failed to act synergistically.

show abstract

mentioning

confidence: 49%

Outbreak of Multiply Drug-Resistant Proteus mirabilis Originating in a Surgical Intensive Care Unit: In Vitro Susceptibility Pattern

Yoshikawa

Shibata

Chow

et al. 1978

Antimicrob Agents Chemother

View full text Add to dashboard Cite

show abstract

“…Of the 13 other patients, the source was the genitourinary VOL. 17,1980 jig/ml). In the amikacin group, two of the six patients were cured, and three improved (one cure with reinfection, one clinical improvement with bacteriological failure, and one patient improved but died from pulmonary disease after only 4 days of therapy).…”

Section: Resultsmentioning

confidence: 99%

“…It is resistant to two of the enzymes that inactivate gentamicin (17,21) and has significantly less ototoxicity (19) and nephrotoxicity than gentamicin in experimental animals (7,13,15). In open clinical trials, it has been therapeutically effective and appears to have less cochlear toxicity than other aminoglycosides (2, 5; 11,12,16,22,29,30).…”

mentioning

confidence: 99%

“…Netilmicin is a new aminoglycoside active in vitro against a wide variety of Enterobacteriaceae and Pseudomonas aeruginosa (4,12,17,21,23,24). It is resistant to two of the enzymes that inactivate gentamicin (17,21) and has significantly less ototoxicity (19) and nephrotoxicity than gentamicin in experimental animals (7,13,15).…”

mentioning

confidence: 99%

“…The mean magnesium content of the broth was 0.28 mg/100 ml, and mean calcium content was 0.28 mg/100 ml. Organisms were considered resistant to gentamicin or netilmicin if the minimal inhibitory concentration (MIC) was 216 tLg/ ml and resistant to amikacin if the MIC was -32 ,ug/ ml (17,19,20 Nephrotoxicity was defined as an increase irq serum creatinine of >0.4 mg/100 ml if the base-line creatinine was <3.0 mg/100 ml and an increase of >0.9 mg/100 ml if the base-line creatinine was >3.0 mg/100 ml (27,28). If other factors were present such as shock, furosemide, congestive heart failure, other aminoglycosides, sulfonamides, or cephalosporins, the reaction was judged possible or doubtful.…”

mentioning

confidence: 99%

See 2 more Smart Citations

Prospective comparative study of efficacy and toxicity of netilmicin and amikacin

Bock¹,

Edelstein²,

Meyer³

1980

Antimicrob Agents Chemother

View full text Add to dashboard Cite

Eighty patients were treated with either amikacin or netilmicin in a prospective randomized study of serious gram-negative bacillary infections, including 11 due to gentamicin-resistant pathogens. Thirty-six treated with netilmicin and 35 treated with amikacin were evaluable for efficacy or toxicity, or both. The overall groups differed significantly only in age. There were no significant differences in efficacy of the two drugs. There were no statistically significant differences at the 95% level between the netilmicin group and the amikacin group with respect to nephrotoxic reactions (38 versus 28%, respectively) or ototoxic reactions (9 versus 25%, respectively). Further comparative trials of netilmicin and other aminoglycosides appear warranted before it is widely used.

show abstract

Netilmicin Sulfate: A Comparative Evaluation of Antimicrobial Activity, Pharmacokinetics, Adverse Reactions and Clinical Efficacy

1983

View full text Add to dashboard Cite

Netilmicin, the 1-N-ethyl derivative of sisomicin, is a new aminoglycoside antibiotic that was recently marketed in the United States. Its role in therapeutics is not yet established. The pharmacokinetic profile of netilmicin is very similar to that of gentamicin. Its antimicrobial spectrum and clinical efficacy is similar to that of gentamicin, tobramycin and amikacin. It is less active in vitro against Pseudomonas aeruginosa that gentamicin and tobramycin, but in clinical trials the efficacy of netilmicin against the organism has been similar to other aminoglycosides. Netilmicin is active against some gentamicin and tobramycin-resistant strains of gram-negative bacilli, particularly those harboring adenylating and phosphorylation enzymes. Most of these strains are sensitive to amikacin as well, and amikacin is also active against most netilmicin-resistant strains of these bacteria. Therefore, amikacin remains the aminoglycoside of choice against gentamicin tobramycin and netilmicin-resistant gram-negative bacilli. In comparison to other currently available aminoglycosides, a lower frequency of nephrotoxicity and ototoxicity has been observed in laboratory animals given netilmicin. This has not been unequivocally demonstrated in humans. The frequency of nephrotoxicity in humans has been similar to that of other aminoglycosides. The frequency of ototoxicity associated with netilmicin in humans has been low but not significantly less than in other aminoglycosides, except in one trial. If further studies document a significantly lower frequency of ototoxicity with netilmicin, it may become the aminoglycoside of choice for patients with significant risk factors for ototoxicity, such as advanced age, renal impairment, concomitant ototoxic drug therapy and prolonged aminoglycoside administration.

show abstract

In Vitro Susceptibility of Gentamicin-Resistant Enterobacteriaceae and Pseudomonas aeruginosa to Netilmicin and Selected Aminoglycoside Antibiotics

Cited by 29 publications

References 17 publications

Outbreak of Multiply Drug-Resistant Proteus mirabilis Originating in a Surgical Intensive Care Unit: In Vitro Susceptibility Pattern

Outbreak of Multiply Drug-Resistant Proteus mirabilis Originating in a Surgical Intensive Care Unit: In Vitro Susceptibility Pattern

Prospective comparative study of efficacy and toxicity of netilmicin and amikacin

Netilmicin Sulfate: A Comparative Evaluation of Antimicrobial Activity, Pharmacokinetics, Adverse Reactions and Clinical Efficacy

Contact Info

Product

Resources

About